November 18, 2025 — Leads & Copy —
TORONTO, Nov. 18, 2025 — NetraMark Holdings Inc. (CSE: AIAI, OTCQB: AINMF, Frankfurt: PF0) has secured four contracts with a major global pharmaceutical firm to provide advanced AI analytics for late-stage clinical studies. The deals signify an expansion of NetraMark’s collaboration with this leading pharmaceutical company.
Under the agreements, NetraMark will apply its NetraAI platform to clinical data from four pivotal studies. The aim is to identify and characterize patient subpopulations that influence treatment response, placebo response, and overall trial variability. The work seeks to improve understanding of patient populations.
George Achilleos, Chief Executive Officer of NetraMark, said the contracts represent a significant expansion of their ongoing collaboration, and the NetraAI system generates explainable insights from complex clinical datasets. This enables sponsors to better understand their patient populations and make more informed development decisions.
The multi-study analyses will identify subpopulations characterizing treatment and placebo response patterns. NetraMark will also quantify clinical and demographic variables that influence variability in study outcomes.
Each study will use NetraAI, an AI system that identifies high-effect-size subgroups within complex datasets without relying on opaque “black box” modeling. This interpretability aligns with the U.S. Food and Drug Administration’s (FDA) evolving expectations for explainable AI methods in clinical development.
The contracts were executed under an existing master services agreement.
NetraAI includes focus mechanisms that separate small datasets into explainable and unexplainable subsets. The NetraAI uses the explainable subsets to derive insights and hypotheses and increases the chances of a clinical trial success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to “overfitting” which drowns out critical information that could have been used to improve a trial’s chance of success.
NetraMark focuses on developing Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions for the Pharmaceutical industry. Its algorithm parses patient data sets into strongly related subsets, allowing NetraMark to use various ML methods. This transforms the data into intelligent data that activates traditional AI/ML methods and accurately segments diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.
For more information, see NetraMark’s publicly available documents filed on SEDAR+.
Swapan Kakumanu – CFO
swapan@netramark.com
403-681-2549
Source: NetraMark Holdings Inc.
